Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

Medicine, Oncology, Pharmacology +17

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

Shiqing Li, Karl R. Schmitz, Philip D. Jeffrey et al. · Cancer Cell · 2005 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

Clara Montagut, Alba Dalmases, Beatríz Bellosillo et al. · Nature Medicine · 2012 · 506 citations

Medicine, Oncology, Pharmacology +16

A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth

Rob C. Roovers, Maria J.W.D. Vosjan, Toon Laeremans et al. · International Journal of Cancer · 2011 · 278 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains

Karl R. Schmitz, Atrish Bagchi, Rob C. Roovers et al. · Structure · 2013 · 250 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +12